Opinion|Videos|July 1, 2024
IO-TKI Findings in nccRCC from KEYNOTE-B61
Author(s)Martin H. Voss, MD
Following the 2024 ASCO Annual Meeting, Martin H. Voss, MD, discusses long-term follow-up data from the phase 2 KEYNOTE-B61 trial investigating pembrolizumab plus lenvatinib in the first-line treatment of advanced non–clear cell RCC.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- Please discuss long term follow-up data from the phase 2 KEYNOTE-B61 trial investigating pembrolizumab + lenvatinib in the first-line treatment of advanced non-clear cell renal cell carcinoma.
Advertisement
Related to this article
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
3
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
4
Neoadjuvant Botensilimab/Balstilimab Shows Activity in Colon Cancer
5